77204 20200117221627.0 sideral 110479 ART-2018-110479 eng Torres-Ferrus, M. PrevenBox: Evaluation of concomitant use of preventive medications with OnabotulinumtoxinA in migraine 2018 Access copy available to the general public Unrestricted P114 Background: OnabotulinumtoxinA is an effective, tolerable and safepreventive treatment for chronic migraine (CM). Other than a reduc-tion in headache frequency or disability, in CM the withdrawal ofconcomitant preventive medication indicates treatment effectivenessand quality of life improvement. Objective: To characterize the change in the use of oral preventivemedication after treatment with OnabotulinumtoxinA in patientswith migraine. Methods: This is a multicentre study. We consecutively included pa-tients with migraine (ICHD-3) that were on preventive treatment withOnabotulinumtoxinA. We retrospectively collected demographic data, diagnosis of migraine, frequency and intensity changes, number ofcycle and OnabotulinumtoxinA dose. In addition, we listed the initialand current preventive treatment (number of drugs and group) andthe number and cycle of medications withdrawn. We performed aunivariate and logistic regression analysis. Results: We included 542 patients: 87.6% women, mean age 47.6 ±11.7 years. A 89.3% had chronic migraine and 10.8% had high fre-quency episodic migraine. The mean reduction in frequency aftertreatment was 13.4±8.2 headache days/month. At baseline, a 91.3%took other preventives and during treatment with Onabotulinumtox-inA a 58.6% withdrew at least one drug, 25.8% stopped completelyall oral preventive drugs. Factors associated with withdrawal were:being male, having >50% response in frequency and intensity, thenumber of infiltrations and a shorter chronification period until thefirst OnabotulinumtoxinA administration (p <0.05). The multivariateanalysis showed that a better response in intensity (OR:1.8 [1.4-2.2], p<0.001), a greater number of infiltrations (OR:1.1 [1.0-1.2], p<0.001)and a shorter chronification period (OR:0.994 [0.992-0.997], p<0.001)were predictors of withdrawal. The ROC curve, showed that 6 Onabo-tulinumtoxinA cycles was the cut-off point that better predicted oralpreventive medication withdrawal (p <0.001). Conclusions: Treatment with OnabotulinumtoxinA reduces the use ofother preventive medications for migraine. The highest probability ofwithdrawal occurs after 6 cycles of treatment. info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 3.918 2018 CLINICAL NEUROLOGY 46 / 199 = 0.231 2018 Q1 T1 NEUROSCIENCES 79 / 266 = 0.297 2018 Q2 T1 1.106 2018 Anesthesiology and Pain Medicine 2018 Q1 Neurology (clinical) 2018 Q1 Medicine (miscellaneous) 2018 Q1 info:eu-repo/semantics/conferenceObject info:eu-repo/semantics/publishedVersion (orcid)0000-0001-5139-6031 Santos Lasaosa, S. Universidad de Zaragoza Peral, A.G. Lainez, J.M. Viguera Romero, J. gago Veiga, A.B. Irimia, P. Sanchez del Rio, M. Asskour, L. Gallardo, V.J. Pozo-Rosich, P. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 19, Suppl. 1 (2018), P114 [1 pp] J. headache pain The Journal of headache and pain 1129-2369 https://thejournalofheadacheandpain.biomedcentral.com/track/pdf/10.1186/s10194-018-0900-0 Texto completo de la revista 73808 http://zaguan.unizar.es/record/77204/files/texto_completo.pdf Versión publicada 111901 http://zaguan.unizar.es/record/77204/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:77204 articulos driver 2020-01-17-21:58:09 ARTICLE